A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use

Description

The goal of this study is to measure the effects of using Tradipitant after GLP-1R agonist use on nausea and vomiting in healthy overweight, class I, or class II obese volunteers. The study is placebo-controlled with two treatment arms.

Conditions

Obesity

Talk to us

Study Overview

On this page

Study Details

Study overview

The goal of this study is to measure the effects of using Tradipitant after GLP-1R agonist use on nausea and vomiting in healthy overweight, class I, or class II obese volunteers. The study is placebo-controlled with two treatment arms.

A Proof of Concept, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Tradipitant on Nausea and Vomiting After GLP-1R Agonist Administration in Healthy Overweight Class I or Class II Obese Volunteers

A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use

Condition
Obesity
Intervention / Treatment

-

Contacts and Locations

Los Angeles

Vanda Investigational Site, Los Angeles, California, United States, 90025

Rochester

Vanda Investigational Site, Rochester, Minnesota, United States, 55905

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Body Mass Index 25-40 kg/m\^2 inclusive
  • * No serious medical problems or chronic diseases, specifically no type I or type II diabetes
  • * Another disorder that contributes to gastrointestinal symptoms
  • * History of intolerance and/or hypersensitivity to NK-1 receptor antagonists
  • * History of intolerance and/or hypersensitivity to GLP-1 receptor agonists
  • * Exposure to any investigational medication within the past 60 days

Ages Eligible for Study

18 Years to 65 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Vanda Pharmaceuticals,

Vanda Pharmaceuticals, STUDY_DIRECTOR, Vanda Pharmaceuticals

Study Record Dates

2025-07-06